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ABSTRACT 
Characterization of the Role of Exopolysaccharides in the Infection Cycle of Bacteriophage 
Petty. (May 2015) 
 
Jacob Lancaster 
Department of Biochemistry and Biophysics 
Texas A&M University 
 
Research Advisor: Dr. Ryland Young 
Department of Biochemistry and Biophysics 
 
Acinetobacter baumannii is a Gram-negative nosocomial pathogen that has been difficult to 
eradicate from hospital settings due to its ability to form biofilm and colonize biotic and abiotic 
surfaces. Phages may represent an alternative to antibiotic therapy and prophylaxis for biofilm-
forming bacteria, but the interaction between phages and encapsulated bacteria such as A. 
baumannii is not well understood. Recently, bacteriophage Petty was isolated against A. 
baumannii strain AU0783. Analysis of its genome suggested that it encoded a depolymerase that 
degrades the host capsular exopolysaccharide (EPS). The gene was cloned and the purified 
protein was shown to reproduce the halo phenotype observed around phage Petty’s plaque, 
degrade purified host EPS, and affect biofilm formation of 5 different A. baumannii isolates. It is 
our aim to determine the cellular requirements for Petty to infect the host cell by characterizing 
the EPS of bacterial mutants of AU0783 that are resistant to phage infection. We isolated 42 
mutants of AU0783 resistant to Petty and determined the titer of the phage. The capsule of these 
mutants and the wild-type strain was observed and its thickness measured.  The ability of the 
mutants to produce biofilm was assessed using a microtiter plate assay. The EPS of 8 mutant 
strains was purified; the ability of the phage’s depolymerase to degrade EPS and produce 
reducing ends was measured using a colorimetric assay and the effect of the enzyme on the 
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viscosity of EPS solutions was established.  No plaques were observed under the given 
conditions in 91% of the Petty-resistant mutants isolated (EOP <10-7). The titer of the phage on 
the remainder of the mutant strains was reduced 3 to 7 orders of magnitude, depending on the 
mutant. Eight mutants were selected for further studies, based on biofilm production and on 
capsule formation compared to the wt strain AU0783. Purified EPS isolated from mutants B11, 
D6, and E8 was unable to be degraded by the depolymerase of Petty, as judged by colorimetric 
assay, and by the viscosity of the capsular polysaccharide when treated with the enzyme. The 
EPS viscosity of mutant D14 was reduced when treated with active depolymerase, but the halo 
phenotype was not reproduced on a bacterial lawn.  Studies aimed at finding phage host range 
mutants that would infect these selected strains are underway.  The differences between these 
phages and the mutant strains will give insight on the mechanism of phage infection of 
encapsulated A. baumannii.  
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CHAPTER I  
INTRODUCTION 
 
Acinetobacter baumannii 
Acinetobacter baumannii is a nonmotile, Gram-negative, opportunistic pathogen, with some 
strains being multi-drug and pan-drug resistant (1) Though this bacterium is thought to be 
commonly found in soil and water, due to the fact that it is opportunistic most of the infections 
due to A. baumannii are found in places with immunocompromised patients, such as a hospital 
intensive care unit (ICU) (2). Resistance to unfavorable environmental conditions, such as 
desiccation, as well as the ability to survive on biotic and abiotic surfaces due to its production of 
biofilm, makes it a frequent cause of outbreaks (3).  Also due to its natural competency and 
resistance to beta lactams and some disinfectants, the widespread growth of the bacteria allows 
for easy transmission to patients and infection that is hard to treat (4).  Some of the infections 
caused by the bacterium include bacteremia, pneumonia, meningitis, urinary tract infection, and 
wound infection (5). Up to 1% of the nosocomial infections in an ICU are due to multidrug 
resistant A. baumannii strains (2).   
Biofilm 
Biofilm is defined as a community of cells characterized by their irreversible attachment to one 
another and their embedding in an extracellular matrix that the group of cells has produced (4).  
This extracellular matrix is composed mostly of capsular EPS, proteins, DNA, polysaccharides, 
and even cell debris (6). Biofilm gives microorganisms an increased tolerance to antimicrobial 
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agents such as antibiotics or chemicals due to the physical barrier between the substance and the 
cells (6). However, not all strains of A. baumannii form biofilm (7), 74% of ICU A. baumannii 
isolates form biofilm and are multi drug (8).  The production of biofilm by A. baumannii is a 
multiple step process (3). The first step occurs when pili and surface proteins form and adhere to 
a surface allowing for the formation of micro-colonies.  Once the micro-colonies form, quorum 
sensing directs biofilm formation.  The production of acyl-homoserine lactone by a feedback 
loop acts as an up-regulator of biofilm formation.  When the acyl-homoserine lactone is 
inactivated the reduction in biofilm is approximately 30-40% meaning that bacterial cell 
communication with respect to cell density is an integral part of biofilm formation (3). The most 
abundant of the substances in biofilm is capsular EPS.  The capsule in A. baumannii is secreted 
in the wzy-dependent process, and is responsible for a slight resistance to phage as well as an 
increase in viscosity of the medium that leads to a decrease in phage spreading (9, 10). 
Bacteriophage Petty 
A novel bacteriophage was recently isolated against the clinical A. baumannii isolate AU0783 in 
the Center for Phage Technology.  The phage has podophage morphology and was thus named 
Petty (Figure 1).  
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Figure 1. The transmission electron microscope image of podophage Petty.  The bacteriophage 
has a capsid diameter of approximately 60 nm. 
When bacteriophage Petty infects AU0783, a halo is observed around the plaques (figure 2), 
indicating the presence of a depolymerase - an enzyme that degrades capsular EPS (11).  
Previously reported proteins with depolymerase activity have been found to be tail fibers or tail 
spikes (12).  After sequencing the 40.3 kb genome, gene 39, a putative tail fiber, was 
hypothesized to have EPS depolymerase activity. The 101.4 kDa Gp39, named Dpo1, was 
expressed using a hyper-expression clone and purified. The purified protein product was able to 
reproduce the halo phenotype on lawns of AU0783, as shown in Figure 3, and degrade purified 
EPS, reducing viscosity. The EPS polymerase is predicted to play a role in adsorption and 
infection of the host cell (11). The current hypothesis about Dpo1’s role in phage infection is that 
the bacteriophage uses the depolymerase to degrade the EPS layer that is blocking the surface 
receptors so that Petty can bind to the receptors and continue with infection (11). 
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Figure 2. Tail fiber depolymerase causes halo phenotype formation around bacteriophage 
plaque.  Phage Petty plated on AU0783 producing the halo phenotype due to EPS degradation. 
 
                                                             
Figure 3. Degradation of capsular EPS by purified Dpo1.  Using the Dpo clearing assay, 
dilutions of Dpo1 were spotted on a lawn of wtAU0783. 
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Depolymerase 
Depolymerases are described as enzymes with the ability to degrade capsular 
exopolysaccharides.  Bacteriophage PK1E, which also encodes a depolymerase, produces an 
Endo-N-acetylneuraminidase (Endo N) from a family of closely related phage-encoded 
glycosidases.  As part of the tail structure, the glycosidases can degrade the homopolymeric α-
2,8-linked sialic acid (PSA) that has been found as components of the capsule in sepsis- and 
meningitis- causing bacterial pathogens, such as PK1E’s host Escherichia coli K1. Endo N acts 
like a polymer when in solution, and when Dpo1 is in solution it acts as a hexamer.  The 
degradation of PSA also causes a halo phenotype like that seen in the degradation of EPS by 
Dpo1 (11, 12).  Thus, we can infer that Dpo1 is in fact a depolymerase. 
Bacteriophage Therapy  
There are currently very few effective procedures for removing the persistent biofilm producing 
strains of the opportunistic pathogen, A. baumannii, from hospital environments.  This causes an 
increased risk of immunocompromised patients acquiring an antibiotic resistant infection (1).  
d’Herelle successfully used bacteriophages as an alternative to antibiotics in 1919 when treating 
dysentery (13).  The narrow range of the bacteriophage is advantageous to the wide host range of 
antibiotics because it does not disrupt other normal gastrointestinal flora. Not only can 
bacteriophage be used as therapeutic agents but so can phage gene products and components.  
Such an example is the phage encoded lysin enzyme that was used to treat dairy starter cultures 
to remove Listeria monocytogenes (14).  Specific criteria are required for phage to be eligible for 
phage therapy, these require that the phage be lytic, infect faster then the rate at which they are 
removed from the site of treatment, and have no deleterious factors (15). Today, bacteriophages 
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are being widely used in Russia, Georgia, and Poland though elsewhere in the world 
bacteriophage still remains an unutilized source of antibacterial treatment (16).  Theoretically, 
the purified depolymerase of bacteriophage Petty can be used like the lysin enzyme of Listeria 
monocytogenes and remove A. baumannii from both abiotic and biotic surfaces (14).   
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CHAPTER II  
MATERIALS AND METHODS 
 
Strains media and general methods  
Tryptic soy broth (TSB) was used for all cultures and agar plates.  For all plaque assays, a .75% 
overlay (top agar) was plated on 1.5% underlay (bottom agar).  The host strain, A. baumannii 
AU0783, was used as a wild type standard for all experiments. 
Host strain mutant hunt 
Mutants of the host strain, AU0783, were discovered by preforming a standard pre-absorption 
assay (5) using 100 µL each of AU0783 and Petty.  After incubating overnight (O/N) at 37°C, 42 
colonies that survived the bacteriophage infection were collected.  Mutants were passed three 
times and titer (17) of phage Petty was tested for each pass on the mutant versus the wt strain to 
determine stability of the resistance phenotype.  
Evaluation of Dpo1 effect on mutant bacterial lawns  
The depolymerase of phage Petty, Dpo1, was expressed using a hyper-expression clone and 
purified.  When spotted on a lawn of wtAU0783 cells, the purified enzyme alone is able to 
reproduce the halo phenotype as seen in Figure 3.  To test the susceptibility to the depolymerase, 
a Dpo clearing assay was done by spotting 10-fold depolymerase dilutions, beginning with an 8.5 
µg/mL stock, till the halo phenotype was no longer observed. The highest dilution at which the 
enzyme was able to produce a halo was recorded.  
Microtiter dish biofilm formation assay  
All procedures from the O’Toole’s methodology (18) were followed with the exception of 
biofilm growth and quantification.  To grow biofilm, the mutant and host strains were incubated 
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O/N at 37°C on a shaking platform.  The samples were diluted 10-fold in lysogeny broth (LB) 
and the absorbance at OD 550 nm was measured.  The cultures were adjusted to an absorbance 
of 1 at OD 550 nm. The newly diluted cultures were then diluted again by 100-fold in LB, and 
100 µL of the dilution was added in 3 wells of a 96 well plate. The plate incubated at 37°C for 3 
days to allow for biofilm growth. To clean the wells, the cultures were emptied and the wells 
were rinsed with 150 µL of dH2O three times.  After cleaning the wells, 150 µL of .01% crystal 
violet stain was added and allowed to set for 10 minutes.  The wells were cleaned again using 
150 µL of dH2O to rinse three times. To quantify the biofilm, 150 µL of 95% ethanol was added 
to each of the wells and left at room temperature for 15 min.  The content of the 96 well plate 
was then transferred into a new 96 well plate and the absorbance was read at 590 nm. 
EPS Purification  
O/N cultures were made for the mutant and host strains.  150 µL of each culture were spread 
onto 20-40 150 x 50 mm petri dishes and incubated at 37°C for 5-7 days depending on the strain. 
To harvest the bacteria, the plates were flooded with 10 mL of 0.9% saline (w/v) then the 
bacteria were scraped off of the plate and transferred into a 500 mL centrifuge bottle using a cell 
scraper. 5% phenol (v/v) was added and stirred for 5 hours.  The mixture was then centrifuged 
for 50 minutes at 5,000 rpm in a Beckman J2-21 centrifuge to pellet the insoluble material.  The 
supernatant was then aliquoted into two 500 mL centrifuge bottles and 5 volumes of 95% ethanol 
was added and left O/N at 4°C.  The EPS precipitate was pipetted out and washed twice with 25 
mL of 95% ethanol, centrifuging in a Sorvall legend XTR centrifuge for 20 minutes at 11,500 
rpm at 4°C each time.  After the last wash, the EPS was allowed to dry O/N.  EPS pellets were 
resuspended in 25 mL sterile dH2O and centrifuged for 20 minutes at 11,500 rpm at 4°C.  The 
supernatant was decanted and saved and the pellet was resuspended in 25 mL sterile dH2O, and 
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spun down again.  The two supernatants were pooled and centrifuged for 40 minutes at 11,500 
rpm at 4°C to pellet the last of insoluble material.  DNase and RNase were added to the pooled 
supernatant mixture to the following final concentrations: 25 mM Tris HCL pH7.5, 50 mM 
NaCl, 5 mM MgCl2, 1 µg/mL DNase, and 1 µg/mL RNase.  This mixture was incubated at 37°C 
for 1.5 hours then heat inactivated in an 80°C water bath for 10 minutes.  Once heat inactivated, 
the EPS mixture was dialyzed O/N with 6-8 kDa MWCO tubing in 4L dH2O.  The water was 
changed three times. Upon completion of dialysis, the samples were transferred into 50 mL 
falcon tubes and freeze-dried using a Labconco lyophilizer for 5 days or until EPS was dry and 
fluffy.   
Capsule visualization and measurements  
Maneval’s solution (Carolina Labs, NC) was used to stain cells growing in liquid culture. The 
staining protocol described by Maneval (19) was followed and capsule images were taken at 
1000X magnification on a Nikon Eclipse Ti. Using these images along with the NIS- Elements 
AR Analysis program the capsular EPS thickness was measured.   
Viscosity assay  
Three types of solutions were prepared to test viscosity using an Ostwald viscometer.  The first 
solution was 3.5 mL of untreated EPS at a concentration of 2.5 mg/mL diluted in 1X assay buffer 
(2.5 mM Tris, 15 mM NaCl, pH 7.2).  In the second solution, EPS (2.5 mg/mL) in 1X assay 
buffer was mixed with active purified enzyme (15 µg/mL). As a control, a third EPS solution 
(2.5 mg/mL) was mixed with purified enzyme (15 µg/mL) that had been previously incubated at 
95°C for 10 minutes to inactivate the enzyme. The three solutions were incubated at 37°C for 1 
hour in water bath; after incubation, the enzyme was heat inactivated at 95°C for 5 minutes to 
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stop the assay.  The viscosity of these solutions, and that of the 1X assay buffer, was measured at 
20°C, in 3 independent assays.  
Bicinchoninic acid assay for reducing ends  
Two reagents were used in this assay: reagent A contains 5 mM bicinchoninic acid (BCA), 513 
mM Na2CO3, and 288 mM NaHCO3, reagent B contains 5 mM CuSO4 and 12 mM L-serine.  The 
BCA working reagent was made fresh in a 1:1:2 ratio of reagents A, B, and dH2O.  A master mix 
was made that included 100 µL of 10X assay buffer (25 mM Tris, 150 mM NaCl, pH 7.2), 100 
µL of 5 mg/mL EPS, and 750 µL dH2O.  95 µL of the master mix was aliquoted into 8 
microcentrifuge tubes. The tubes were left open and placed into a 37°C heat block and allowed 
to sit for 5 minutes.  5 µL of the enzyme stock (200 nM) was added to each tube, and was then 
mixed by flicking.  The tubes were placed back at 37°C.  At 5, 10, 20, 30 minutes, a pair of tubes 
was removed and placed into the 95°C heat block for 5 minutes.  The tubes were removed and 
cooled to room temperature.  After all time points had been taken and tubes had been cooled, the 
tubes were reopened and 1 mL of BCA assay reagent was added to each tube.  The samples were 
mixed by vortexing and the tubes were placed into a 95°C heat block for 15 minutes.  The 
samples were cooled to room temperature for 20 minutes and absorbance was read at 560 nm.  
Two controls (negative and positive) were run alongside the EPS sample.  The negative control 
had 10 µL 10X assay buffer and 90 µL mqH2O.  The positive control had 10 µL 2 mM glucose, 
10 µL 10X assay buffer, and 80 µL mqH2O.  This assay was repeated for all working mutants 
and host strains. 
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CHAPTER III  
RESULTS 
 
Identification of phage Petty resistant AU0783 mutants 
42 mutants of wtAU0783 were selected from bacterial colonies that survived infection by phage 
Petty.  These bacteria were selected to help understand the mechanism of phage resistance.  To 
determine if the phage resistance phenotype was stable in the 42 selected mutants, mutant 
bacteria were platted successively, phage Petty was spot tittered on the lawns, and titer was 
determined (Table 1).  The susceptibility of the mutants to pure Dpo1 enzyme was also 
determined.  The Dpo clearing assay helped to determine if the mutants would produce a halo 
phenotype and the lowest dilution at which the halo phenotype was observed is recorded in Table 
1.  By comparing the three-titer trials, 33 of the mutants were determined to be stable and 9 were 
false positives. Dpo1 also had an effect in vivo causing the halo phenotype to occur with of the 9 
mutants, all of which were either unstable or seemed to be wild type. 
Phage resistance in bacteria can occur at three main steps.  The first is adsorption; during 
adsorption the phage will have some sort of physical barrier such as a capsule or the loss of a 
phage receptor.  The second step affected is the uptake of the phage genome into the cytoplasm.  
During this step, if a prophage is present it will block the genome of the bacteriophage that is 
currently infecting the cell from entering the cytoplasm.  The last step is host take-over.  This is 
the last time the cell can stop infection.  The presence of restriction enzymes, a CRISPR system, 
and/or a toxin-antitoxin system may destroy the bacteriophage genome once it enters the 
cytoplasm (20).   
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In the case of the 42 mutants selected, phage resistance is most likely due to defects in 
adsorption. When the capsule changes, the depolymerase may no longer be as effective or the 
bacteria may have lost a receptor recognized by the depolymerase  
 
Table 1.  Identification of phage Petty resistant AU0783 mutants. 42 independent bacterial 
colonies that survived infection by Petty were selected and each of the mutants was named with 
an arbitrary letter and number. Phage titer was determined on each of the 42 mutants as well as 
wtAU0783. The ability of Petty’s depolymerase to reproduce the halo phenotype on lawns of the 
mutant strains was also assessed.  Starting at a concentration of 8.49 µg/mL and diluting 10 fold 
until extinction, the highest dilution at which Dpo1 produced the halo phenotype was recorded.  
Those mutants that were not affected by the enzyme are marked with a zero. 
 
Titer DPO 
 Trial 1 Trial 2 Trial 3 Trial 1 Trial 2 Trial 3 
B11 >109 >109 >109 0 0 0 
B5 >109 >109 >109 0 0 0 
B7 >109 >109 >109 0 0 0 
B16 >109 >109 >109 0 0 0 
B15 >109 >109 >109 0 0 0 
B13 >109 4.6 x 108 3.6 x 107 0 10-5 10-4 
D2 >109 >109 >109 0 0 0 
D5 >109 >109 >109 0 0 0 
D6 >109 >109 >109 0 0 0 
D7 >109 >109 >109 0 0 0 
D14 >109 >109 >109 0 0 0 
D16 >109 >109 >109 0 0 0 
E11 >109 >109 >109 0 0 0 
E9 >109 >109 >109 0 0 0 
E13 >109 >109 >109 0 0 0 
E8 >109 >109 >109 0 0 0 
E6 >109 >109 >109 0 0 0 
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Table 1. Continued 
 Titer DPO 
 Trial 1 Trial 2 Trial 3 Trial 1 Trial 2 Trial 3 
E3 >109 >109 >109 0 0 0 
F3 >109 >109 >109 0 0 0 
F4 >109 >109 >109 0 0 0 
F5 >109 >109 >109 0 0 0 
F10 >109 >109 >109 0 0 0 
F8 >109 >109 >109 0 0 0 
F7 >109 >109 >109 0 0 0 
A15 >109 >109 >109 0 0 0 
A11 4 x 107 2 x 109 1.8 x 109 10-3 10-5 10-4 
A2 >104 >106 8.8 x 107 10-3 10-4 10-4 
A6 >109 >109 >109 0 0 0 
A7 >104 4.6 x 107 3.6 x 107 10-3 10-4 10-5 
A14 2.6 x 106 7 x 107 7.6 x 107 10-3 10-5 10-5 
C2 >109 >109 >109 0 0 0 
C3 >109 >104 >104 0 10-4 10-4 
C6 >109 >109 >109 0 0 0 
C9 >106 5.2 x 109 2.8 x 109 10-3 10-5 10-5 
C12 >104 1.8 x 108 1.12 x 108 10-3 10-4 10-4 
C15 >109 2 x 109 >109 0 10-4 0 
G9 >109 >109 >109 0 0 0 
G1 >109 >109 >109 0 0 0 
G8 >109 >109 >109 0 0 0 
G6 >109 >109 >109 0 0 0 
G10 >109 >109 >109 0 0 0 
G11 >109 >109 >109 0 0 0 
AU0783 
(WT) 6.5 x 109 6.4 x 109 4 x 109 10-5 10-5 10-5 
 
Characterization of biofilm formation of AU0783 mutants 
To determine the ability of the mutants selected to form biofilm, a colorimetric biofilm assay was 
preformed.  This assay allowed for the indirect determination of the amount of biofilm by 
staining it with crystal violet and viewing the normalized cell absorbance ratio, A590/A550 (Figure 
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4a,b). Approximately 80% of the mutants produced no halo phenotype indicating a possible 
change in capsular EPS thus biofilm production. Mutant E8 produces the same amount of 
biofilm as AU0783 and is also resistant to phage infection.  This lead to the hypothesis, that there 
may be other causes of resistance rather than just a change in the amount of biofilm produced. 
 
 
 Figure 4a.  Characterization of biofilm formation of AU0783 mutants.  Cells were grown for 
three days at 37°C in a 96 well plate and absorbance was measured (A550).  Biofilm formation 
was assessed by staining with crystal violet and measuring absorbance (A590), crystal violet 
absorption was measured in each well and each measurement was done in triplicate. The graph 
was plotted using the ratio of A590/A550 to normalize to cell growth.  The error bars show the 
standard deviation of the mean for each of the trials.  Once again the stability of the most of the 
mutants by their biofilm production is seen.  Table continued in next figure. 
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Figure 4b. Continuation of Figure 2a. 
Characterization of mutant capsular EPS 
While the biofilm assay can be used to determine if the mutant strain produces more or less 
biofilm than the wt strain, a more exact measurement of the capsular EPS of the mutants was 
needed. To visualize this, the mutants were stained with Congo red and Maneval’s solution then 
images were taken at a magnification of 1000x using a Nikon Eclipse Ti.  Using these images, 
measurements of the capsular EPS thickness were taken using the program NIS- Elements AR 
Analysis (Figure 5).  Approximately 200 cells per mutant were measured (Figure 6).  While most 
of the mutants produce more EPS than the wt, strains E8, C9, and A11 produce a thinner capsule. 
Using the size of the capsule is important when determining why the bacteriophage is not 
infecting the bacterial mutants.  As described earlier, one of the major types of phage resistance 
is due to a physical barrier blocking phage adsorption (20).  If the capsule is getting larger due to 
a mutation it could cause the phage receptor site to be blocked by EPS, and if the capsule is 
getting smaller the loss of EPS could cause the loss of the receptor all together (21).   
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Figure 5. Characterization of mutant capsular EPS. The host and mutants were visualized by 
Maneval’s stain and magnification at 1000x using a Nikon Eclipse Ti. The capsule thickness was 
measured using the program NIS- Elements AR Analysis. Representative images from the strains 
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are as follows A. AU0783, B. All, C. B11, D. A7, E. A14, F. C9, G. D6, H. D14, and I. E8. 
 
Figure 6. Characterization of mutant capsular EPS. The width of the EPS was averaged by 
measuring the capsular EPS thickness of 200 cells per mutant using the program NIS- Elements 
AR Analysis. 
 
Evaluation of Dpo1 degradation of mutant EPS 
Further evaluation of the mutant EPS was done using both a viscosity and BCA assay.  It was 
shown from the Dpo1 clearing assay that E8, B11, D6, and D14 are not affected by Dpo1 in vivo 
while C9, A7, A11, and A14 are.  To determine if the EPS was affected in vitro, purified EPS 
was treated with an active enzyme as well as a heat inactivated enzyme.  The viscosities were 
measured using an Ostwald viscometer in triplicate (Figure 7).  
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The viscosity of mutant D14 is comparable to wild type and is brought to that of buffer when 
treated with active enzyme.  This is interesting because in vivo D14 has no visible halo 
phenotype indicating that Dpo1 is not degrading the EPS. One of the possible explanations as to 
why no halo is seen when in vivo, is that the bacterial mutant is producing capsular EPS faster 
than the depolymerase can degrade it.  
While as of now bacteriophage are not being used to their full potential in the United States, it is 
important to note that phage products are allowed and are being used today, and because of this 
there is a possibility for Dpo1 to be used as a disinfectant in settings where A. baumannii is 
prevalent such as the ICU (14).   
 
Figure 7.  Evaluation of Dpo1 degradation of mutant EPS.  The viscosity of the 3 solutions, 
untreated, inactive, and active, for each mutant were measured using an Oswald Viscometer.  For 
mutants E8, D6, and B11, Dpo1 had no effect in vitro on the EPS, while for the D14 mutant 
Dpo1 degraded the EPS to the viscosity of buffer.  This is similar to the effect that Dpo1 has on 
the wt host AU0783.   
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Purified recombinant, Dpo1, the depolymerase of phage Petty, generates reducing ends when 
degrading purified EPS from the host strain, AU0783.  To further assess the effect of the purified 
enzyme on the purified EPS of the mutants, the BCA assay was preformed.  The assay’s working 
reagent’s copper component is reduced from Cu2+ to Cu+ giving a color change from blue to 
purple.  The extent of the color change proportionally indicates the amount of reducing ends in 
solution.  Presumably, if the mutant EPS is degraded, the amount of reducing ends will increase 
allowing for a more exact visualization of EPS degradation then that seen in the viscosity assay.   
Figure 8 shows the results for D14, D6, and E8. As seen in the viscosity assay, the purified D14 
EPS is degraded; so is the purified D6 EPS. 
 
Figure 8. Evaluation of Dpo1 degradation of mutant EPS.  The purified EPS of 3 mutants and 
host were put into solution at a concentration of 5mg/ml. From these diluted EPS samples, a 
master mix was produced.  5µl of depolymerase was added and two samples were taken for each 
time point of 5, 10, 20, and 30 minutes at 37°C.  The samples were heat inactivated for 5 minutes 
at 95°C then cooled to room temperature.  Once all time points were taken, 1 ml of BCA assay 
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reagent was added and the samples were heated at 95°C for 15 minutes.  The graph was plotted 
using the average of A560 for two independent assays.  
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CHAPTER IV  
CONCLUSIONS 
 
To begin, 42 candidate mutants of AU0783 were selected from colonies that survived exposure 
to phage Petty.  Of these, we continued with 8 based on biofilm production and capsule 
formation compared to the wt strain AU0783. In theory there are three different possibilities as to 
why phage resistance is occurring: 1) the amount of capsule is reduced impairing phage 
absorption; 2) due to a mutation, the capsular EPS structure has changed; 3) some sort of internal 
insensitivity to bacteriophage Petty has emerged, again as a result of mutation.  These mutants of 
the clinical strain AU0783 were shown to be resistant to infection by phage Petty due to changed 
capsule characteristics. Phage resistance could be explained by a change in capsular composition, 
thus causing the insensitivity of the EPS of the mutants to depolymerase activity.  The amount of 
capsule produced by the bacterial mutants could also affect the absorption of the bacteriophage 
Petty.  Further adsorption assays will assess the ability of the phage to absorb to mutant cells.  
Dpo1 was not effective against mutant D14 when plated with phage Petty.  However, the 
purified EPS of this mutant is sensitive to the phage’s depolymerase and its degradation produces 
reducing ends.  The mechanism of resistance of this mutant cannot be explained by changes in 
the capsular characteristics that were assessed.   
Genomic DNA of these mutants has been sent for sequencing to further investigate which of the 
three resistance possibilities is occurring for each mutant.   
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